奥曲肽联合应用奥美拉唑治疗肝硬化并上消化道出血的临床意义分析

Analysis of Clinical Significance of Octreotide Combined with Omeprazole in Treatment of Cirrhosis Combined with Upper Gastrointestinal Hemorrhage

目的将奥曲肽和奥美拉唑联合用药治疗肝硬化合并消化道出血患者,对该治疗方法的效果进行探究。方法该次研究对象为2010年2月—2015年7月收诊于该院消化内科的40例肝硬化合并上消化道出血患者,随机分到两组中,每组20例,对照组使用奥美拉唑和垂体后叶注射液,联合组患者奥曲肽和奥美拉唑注射液联合用药。比较两种治疗方案的效果。结果联合用药组的总有效率为95%,与对照组80.0%相比差异有统计学意义(χ~2=7.452,P<0.05),其不良反应发生率为15.0%大大低于对照组45.0%(χ~2=8.516,P<0.05),联合组的住院时间和止血时间也显著低于对照组(t=26.75,P<0.05,t=21.07),以上组间差异均有统计学意义。结论对于肝硬化合并上消化道出血患者采用奥美拉唑和奥曲肽联合治疗方法可以减少患者住院时间,降低出血量,减少不良反应的发生,临床治疗效果显著。

Objective To study the effect of octreotide combined with omeprazole in treatment of cirrhosis combined with upper gastrointestinal hemorrhage. Methods 40 cases of patients with cirrhosis combined with upper gastrointestinal hemorrhage admitted and treated in our hospital from February 2010 to July 2015 were selected and randomly divided into two groups with 20 cases in each, the control group used the octreotide and liquor pituitary, while the combined group were treated with octreotide combined with omeprazole injection, and the treatment effect was compared between the two groups. Results The difference in the total effective rate between the combined medication group and the control group was obvious（95.0% vs 80.0%）,（χ2=7.452,P〈0.05）, and the incidence rate of adverse reactions was much lower than that in the control group（15.0% vs 45.0%）,（χ2=8.516,P〈0.05）, and the length of stay and hemostasis time in the combined group were obviously lower than those in the control group（t =21.07,t =26.75,P〈0.05）, and the differences were statistically significant. Conclusion The octreotide combined with omeprazole in treatment of cirrhosis combined with upper gastrointestinal hemorrhage can reduce the length of stay, bleeding amount and occurrence of adverse reactions, and the clinical treatment effect is obvious.